Armata Pharmaceuticals
Develops bacteriophage cocktails for serious antibiotic-resistant bacterial infections.
Something off on this page? Send us feedback.
Profile
Develops pathogen-specific bacteriophage cocktails for hard-to-treat bacterial infections, with AP-SA02 and AP-PA02 as its main clinical programs. Research is funded through grants, awards, and capital while commercialization awaits clinical success, regulatory approval, and a partner or commercial buildout.
Develops fixed, pathogen-specific bacteriophage cocktails for antibiotic-resistant and difficult-to-treat bacterial infections. The pipeline centers on AP-SA02, an intravenous adjunct to antibiotics for complicated Staphylococcus aureus bacteremia, and AP-PA02, an inhaled candidate for chronic pulmonary Pseudomonas aeruginosa infections; AP-PA03 targets acute Pseudomonas pneumonia at the preclinical stage.
Combines phage discovery, host-range screening, cocktail design, process development, analytics, and cGMP manufacturing in Los Angeles. It has no approved products or commercial infrastructure, while clinical studies, manufacturing scale-up, and eventual commercialization depend on clinical evidence, regulatory approval, funding, and potential partners. Its core manufacturing operation is concentrated in Los Angeles.
Company facts
Key statistics
Year to date −18.9% · Average volume (30d) 127.3K
Analysts
Ratings
Target range
Latest analyst notes
No analyst notes in the last 24 months.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 12, 2026Q2 FY26 | −$0.45 | −$0.27 | +39.3% | $400.0K | $2.5M | +527.5% | +11.83% |
| Aug 11, 2026Q2 FY26 | −$0.48 | −$0.27 | +43.7% | $400.0K | — | — | +1.41% |
| May 13, 2026Q1 FY26 | −$0.38 | −$3.16 | −731.6% | $740.0K | $789.0K | +6.6% | −7.03% |
| Mar 25, 2026Q4 FY25 | −$0.19 | −$0.51 | −168.4% | $740.0K | $1.1M | +48.6% | +8.59% |
Financial highlights
| 11 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $491.0K | $2.2M | $0 | $0 | $789.0K | $2.5M | |
| Gross profit | $114.0K | $1.8M | $0 | $0 | $332.0K | $1.9M | |
| Operating income | −$8.2M | −$6.8M | −$7.8M | −$13.8M | −$8.8M | −$10.3M | |
| Net income | −$6.5M | −$16.3M | −$26.7M | −$124.3M | −$115.3M | $74.1M | |
| Diluted EPS | −$0.18 | −$0.45 | −$0.74 | −$3.42 | −$3.16 | −$0.27 | |
| Gross margin | 23.2% | 83.1% | — | — | 42.1% | 76.5% | |
| Operating margin | -1,668.2% | -315.5% | — | — | -1,113.4% | -410.8% |
Fiscal years (4-quarter sums)FY24 $5.2M · FY25 $2.7M
Balance sheet, Jun 30, 2026Cash & short-term investments $24.0M · Total debt $314.0M · Total assets $90.0M · Shareholders' equity −$231.2M
Dividends
No dividends on record.
Ownership
Shares outstanding 36.71M · Float 11.43M · 31.1% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Innoviva, Inc. | 55.47M | 82.70% | 13D | May 13, 2026 |
| Madison Asset Management, LLC | 2.11M | 5.74% | 13F | May 7, 2026 |
| Vanguard Capital Management LLC | 366.0K | 1.00% | 13F | May 15, 2026 |
| Millennium Management LLC | 258.0K | 0.70% | 13F | May 15, 2026 |
| 683 Capital Management, LLC | 137.0K | 0.37% | 13F | May 15, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
View detailsPeers
- Merck
Marketed IV bacteremia antibiotic and standard-of-care option.
- Gilead Sciences
Marketed inhaled antibiotic incumbent in CF Pseudomonas.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Armata Pharmaceuticals | $5.37 | +0.94% | $197.1M | — | — | 59.8 | +15.7% |
| Merck | $148.19 | −0.08% | $366.18B | 118.7 | 17.2 | 5.5 | +5.1% |
| Gilead Sciences | $139.30 | −4.36% | $180.87B | — | 16.0 | 5.9 | +10.2% |
| Median | 118.7 | 16.6 | 5.7 | +7.6% |